Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus

Annals of Clinical and Laboratory Science

Volumn 41, Issue 2, 2011, Pages 131-137

  Kalra, Vaneet K ^a   DeBari, Vincent A ^a,b   Zauk, Adel ^a   Kataria, Preetika ^a   Myridakis, Dorothy ^a   Kiblawi, Fuad ^a  

^a ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^b SETON HALL UNIVERSITY   (United States)

Author keywords

B type natriuretic peptide; BNP; Neonates; Patent ductus arteriosus; Point of care testing; Premature infants

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; IBUPROFEN;

ARTICLE; BLOOD SAMPLING; CAPILLARY BLOOD; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; HUMAN; NEWBORN; PATENT DUCTUS ARTERIOSUS; POINT OF CARE TESTING; PREMATURITY; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUCTUS ARTERIOSUS, PATENT; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NATRIURETIC PEPTIDE, BRAIN; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES;

EID: 80052665003     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Attridge JT, Kaufman DA, Lim DS. B- type natriuretic peptide to guide therapy of Patent Ductus Arteriosus. Arch Dis Child Fetal Neonatal Ed. 2009 May;94(3):F178-82.
2. Wylie J. Treatment of patent ductus arteriosus. Semin Neonatal 2003;8:425-32.
3. Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatal 2001;6:63-73.
4. Korhonen P, Tammela O, Koivisto AM, Laippala P, Ikonen S. Frequency and risk factors in bronchopulmonary dysplasia in a cohort of very low birth weight infants. Early Hum Dev 1999;54:245-58.
5. El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005;90:F419-22.
6. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinmann CS. The use of Bedside assay for Plasma B- type Natriuretic Peptide as a biomarker in the management of Patent Ductus Arteriosus in Premature Neonates. J Pediatr 2005; 147:38-42.
7. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L' Ecuyer T. Role of plasma B-type natriuretic peptide in screening of hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol (2005)25:709-713.
8. Choi M, Lee KH, Eun BL, Yoo KH, Son CS, Lee JW. Utility of rapid B- type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. J Pediatr 2005; 115:255-61.
9. W E Benitz. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol (2010) 30, 241-252.
10. Hammerman C, Shchors I, Schimmel MS, Bromiker R, Kaplan M, Nir A. N-terminal-Pro-B-Type Natriuretic Peptide in Premature Patent Ductus Arteriosus: A Physiologic Biomarker, But Is It a Clinical Tool? Pediatr Cardiol. 2010 Jan;31(1):62-5.
11. Wald RM, Adatia I, Van Arsdell GS, Hornberger LK. Relation of limiting ductal patency to survival in neonatal Ebstein's anomaly. Am J Cardiol 2005; 96: 851-856
12. Cuzick J. A Wilcoxon -type test for trend. Stat Med 1985; 4:87-90.
13. Erdfelder E., Faul F., Buchner A. GPOWER: A general power analysis program. Behavior Research Methods, Instruments & Computer 1996; 28, 1-11.
14. Skinner J. Diagnosis of the patent ductus arteriosus. Semin Neaonatal. 2001 ;6 :49-61.
15. Evans N. Current controversies in the diagnosis and treatment of patent ductus arteriosus in preterm infants. Adv Neonatal Care. 2003 ;3 :168 -177.
16. McDowell G, Shaw C, Buchanan KD, Nicholas DP. The natriurteic paptide family. Eir JClin Invest. 1995:25:291-298.
17. Witthaut R. Science review: Natriuretic peptides in critical illness. Crit Care 2004;8:342-9.
18. Holmes SJ, Espiner EA, Richards AM, Yandle TJ, Frampton C. Renal, Endocrine and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin Endocrinol Metab. 1993;76: 91-96.
19. Levin ER, Gardner DG, Samson WK. Natriuretic Peptides. N Engl J Med. 1998; 339:321-328.
20. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
21. Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, et al. Rapid B-type natriuretic peptide assay accurately diagnose left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2001;144: 834-9.
22. Schirmer H, Omland T. Circulating N-terminal pro- atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromso Study. Eur Heart J 1999;20: 755-63.
23. Yamaguchi H, Yoshida J, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004;43: 55-60.
24. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999;100: 287-91.
25. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105: 2392-7.
26. Friedman WF. The intrinsic physiologic properties of the developing heart. Prog Cardiovasc Dis 1972; 15: 87-111.
27. Mir TS, Laux R, Hellwege HH, et al. Plasma concentrations of aminoterminal pro atrial natriurteic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatr. 2003;112:896-899.
28. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Pediatr. 2001;90:184-191.
29. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma Brain natriuretic peptide as a predictor of hemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond). 2002; 103: 75-77.